Characterization of the Onset, Progression, and Reversibility of Morphological Changes in Mouse Lung after Pharmacological Inhibition of Leucine-Rich Kinase 2 Kinase Activity-Reference-Cited by-同舟云学术

Characterization of the Onset, Progression, and Reversibility of Morphological Changes in Mouse Lung after Pharmacological Inhibition of Leucine-Rich Kinase 2 Kinase Activity

Published:2021-01-28 Issue:1 Volume:377 Page:11-19
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Bryce Dianne K.^ORCID,Ware Chris M.,Woodhouse Janice D.,Ciaccio Paul J.,Ellis J. Michael,Hegde Laxminarayan G.,Kuruvilla Sabu,Maddess Matthew L.,Markgraf Carrie G.,Otte Karin M.,Poulet Frederique M.,Timmins Lauren M.,Kennedy Matthew E.,Fell Matthew J.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference25 articles.

1. PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats

2. Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs

3. LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits;Baptista;Sci Transl Med,2020

4. Pathoanatomy of Parkinson’s disease

5. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to date;Expert Opinion on Therapeutic Patents;2024-07-19

2. LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression;Translational Neurodegeneration;2024-03-04

3. G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage;npj Parkinson's Disease;2024-03-01

4. Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson’s Disease;Journal of Medicinal Chemistry;2023-10-20

5. LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread;2023-10-06